Medtronic PLC Company Profile (NYSE:MDT)

About Medtronic PLC

Medtronic PLC logoMedtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group. The Cardiac and Vascular Group segment includes Cardiac Rhythm & Heart Failure, Coronary & Structural Heart and Aortic & Peripheral Vascula. Its Minimally Invasive Technologies Group segment includes Surgical Solutions and Patient Monitoring and Recovery. Its Restorative Therapies Group segment includes Spine, Neuromodulation, Surgical Technologies and Neurovascular. Its Diabetes Group segment includes Intensive Insulin Management, Non-Intensive Diabetes Therapies and Diabetes Services & Solutions. The Company's subsidiaries include Medtronic, Inc. and HeartWare International, Inc.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Appliances & Equipment
  • Sub-Industry: Health Care Equipment
  • Exchange: NYSE
  • Symbol: MDT
  • CUSIP: 58505510
Key Metrics:
  • Previous Close: $80.74
  • 50 Day Moving Average: $75.85
  • 200 Day Moving Average: $80.09
  • 52-Week Range: $69.35 - $89.27
  • Trailing P/E Ratio: 26.89
  • Foreward P/E Ratio: 16.28
  • P/E Growth: 2.36
  • Market Cap: $110.86B
  • Outstanding Shares: 1,373,047,000
  • Beta: 0.97
  • Net Margins: 14.63%
  • Return on Equity: 12.36%
  • Return on Assets: 6.31%
  • Debt-to-Equity Ratio: 0.58%
  • Current Ratio: 2.35%
  • Quick Ratio: 1.96%
Additional Links:
Companies Related to Medtronic PLC:

Analyst Ratings

Consensus Ratings for Medtronic PLC (NYSE:MDT) (?)
Ratings Breakdown: 8 Hold Ratings, 17 Buy Ratings
Consensus Rating:Buy (Score: 2.68)
Consensus Price Target: $87.71 (8.64% upside)

Analysts' Ratings History for Medtronic PLC (NYSE:MDT)
DateFirmActionRatingPrice TargetDetails
2/23/2017Oppenheimer Holdings, Inc.Reiterated RatingOutperform$84.00 -> $87.00View Rating Details
2/23/2017Leerink SwannBoost Price Target$85.00View Rating Details
2/22/2017WedbushReiterated RatingNeutral$85.00View Rating Details
2/21/2017Needham & Company LLCBoost Price TargetBuy -> Buy$84.00 -> $91.00View Rating Details
2/21/2017Evercore ISIBoost Price TargetBuy$78.00 -> $88.00View Rating Details
2/17/2017Jefferies Group LLCReiterated RatingBuy$88.00View Rating Details
1/8/2017Deutsche Bank AGSet Price TargetBuy$96.00View Rating Details
1/3/2017Morgan StanleyReiterated RatingEqual Weight -> OverweightView Rating Details
1/3/2017Bank of America CorpDowngradeBuy -> Neutral$78.00View Rating Details
1/3/2017J P Morgan Chase & CoDowngradeOverweight -> Neutral$84.00 -> $79.00View Rating Details
11/23/2016Barclays PLCLower Price TargetOverweight$93.00 -> $85.00View Rating Details
11/23/2016BMO Capital MarketsLower Price TargetOutperform$94.00 -> $87.00View Rating Details
11/23/2016Stifel NicolausLower Price TargetHold$91.00 -> $81.00View Rating Details
8/25/2016Credit Suisse GroupReiterated RatingOutperform$92.00View Rating Details
8/23/2016Cowen and CompanySet Price TargetBuy$94.00View Rating Details
8/23/2016Citigroup Inc.Initiated CoverageBuy$63.98 -> $102.00View Rating Details
7/6/2016Goldman Sachs Group, Inc. (The)Reiterated RatingBuyView Rating Details
6/27/2016BTIG ResearchReiterated RatingHoldView Rating Details
6/20/2016ArgusReiterated RatingHold -> HoldView Rating Details
6/15/2016Piper Jaffray CompaniesReiterated RatingOverweight$93.00 -> $94.00View Rating Details
6/13/2016SunTrust Banks, Inc.Boost Price TargetBuy$93.00 -> $98.00View Rating Details
6/8/2016GuggenheimInitiated CoverageNeutralView Rating Details
6/7/2016Wells Fargo & CompanyReiterated RatingBuyView Rating Details
6/1/2016Royal Bank Of CanadaReiterated RatingBuyView Rating Details
3/17/2016NomuraInitiated CoverageBuy$86.00View Rating Details
9/4/2015William BlairReiterated RatingOutperformView Rating Details
6/25/2015Sterne Agee CRTReiterated RatingNeutralView Rating Details
6/4/2015S&P Equity ResearchReiterated RatingBuy$89.00View Rating Details
(Data available from 2/24/2015 forward)


Earnings History for Medtronic PLC (NYSE:MDT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/21/20171/31/2017$1.11$1.12$7.22 billion$7.28 billionViewListenView Earnings Details
11/22/2016Q217$1.11$1.12$7.46 billion$7.35 billionViewListenView Earnings Details
8/25/2016Q117$1.01$1.03$7.17 billion$7.20 billionViewListenView Earnings Details
5/31/2016Q416$1.26$1.27$7.49 billion$7.57 billionViewListenView Earnings Details
3/1/2016Q316$1.06$1.06$6.99 billion$6.93 billionViewListenView Earnings Details
12/3/2015Q216$1.00$1.03$7.10 millionViewListenView Earnings Details
9/3/2015Q116$1.01$1.02$7.30 billionViewListenView Earnings Details
6/2/2015Q415$1.11$1.16$7.18 billion$7.30 billionViewListenView Earnings Details
2/17/2015Q3$0.97$1.04$4.25 million$4.32 millionViewListenView Earnings Details
11/18/2014Q2$0.96$0.96$4.37 million$4.40 millionViewListenView Earnings Details
8/19/2014Q115$0.92$0.93$4.25 billion$4.27 billionViewListenView Earnings Details
5/20/2014Q414$1.12$1.12$4.58 billion$4.60 billionViewListenView Earnings Details
2/18/2014Q314$0.91$0.91$4.15 billion$4.20 billionViewListenView Earnings Details
11/19/2013Q214$0.90$0.91$4.18 billion$4.20 billionViewListenView Earnings Details
8/20/2013Q1 2014$0.88$0.88$4.11 billion$4.10 billionViewListenView Earnings Details
5/21/2013Q4 2013$1.03$1.10$4.39 billion$4.50 billionViewListenView Earnings Details
2/19/2013Q3 2013$0.91$0.93$4.03 billion$4.03 billionViewListenView Earnings Details
11/20/20120.88$0.88$4.10 billionViewN/AView Earnings Details
8/21/2012$0.85$0.85ViewN/AView Earnings Details
5/22/2012$0.98$0.99ViewN/AView Earnings Details
2/21/2012$0.84$0.88ViewN/AView Earnings Details
11/22/2011$0.82$0.84ViewN/AView Earnings Details
8/23/2011$0.79$0.79ViewN/AView Earnings Details
5/24/2011$0.93$0.90ViewN/AView Earnings Details
2/22/2011$0.84$0.86ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Medtronic PLC (NYSE:MDT)
Current Year EPS Consensus Estimate: $4.57 EPS
Next Year EPS Consensus Estimate: $4.96 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163$1.05$1.07$1.06
Q2 201610$1.24$1.29$1.26
Q3 20167$1.05$1.15$1.09
Q4 20169$1.11$1.27$1.17
Q1 20177$1.00$1.15$1.03
Q2 20177$1.10$1.37$1.16
Q3 20177$1.10$1.15$1.12
Q4 20177$1.27$1.34$1.31
Q1 20185$1.09$1.15$1.13
Q2 20185$1.19$1.32$1.22
Q3 20185$1.19$1.25$1.22
Q4 20185$1.34$1.46$1.40
(Data provided by Zacks Investment Research)


Current Dividend Information for Medtronic PLC (NYSE:MDT)
Annual Dividend:$1.72
Dividend Yield:2.13%
Dividend Growth:25.50% (3 Year Average)
Payout Ratio:57.14% (Based on Trailing 12 Months of Earnings)
37.64% (Based on Current Year Consensus EPS Estimate)
34.68% (Based on Next Year Consensus EPS Estimate)
Track Record:39 Years of Consecutive Dividend Growth

Dividend History for Medtronic PLC (NYSE:MDT)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Medtronic PLC (NYSE:MDT)
Insider Ownership Percentage: 0.25%
Institutional Ownership Percentage: 82.71%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/13/2016Robert C. PozenDirectorBuy13,660$73.21$1,000,048.60View SEC Filing  
11/23/2016James T. LenehanDirectorBuy2,000$73.27$146,540.00View SEC Filing  
9/27/2016Richard KuntzVPSell17,141$86.70$1,486,124.70View SEC Filing  
9/26/2016Richard KuntzVPSell25,199$86.67$2,183,997.33View SEC Filing  
9/15/2016Kendall J. PowellDirectorSell7,907$85.45$675,653.15View SEC Filing  
9/15/2016Omar IshrakCEOSell61,925$84.93$5,259,290.25View SEC Filing  
8/29/2016Bryan C HansonEVPSell15,000$87.00$1,305,000.00View SEC Filing  
7/26/2016Bryan C HansonEVPSell15,000$87.00$1,305,000.00View SEC Filing  
7/15/2016Geoffrey MarthaEVPSell3,766$88.26$332,387.16View SEC Filing  
7/13/2016Gary Lee EllisEVPSell35,495$88.64$3,146,276.80View SEC Filing  
7/13/2016Shirley A JacksonDirectorSell2,104$88.64$186,498.56View SEC Filing  
7/6/2016Carol A. SurfaceSVPSell9,787$87.08$852,251.96View SEC Filing  
7/5/2016Bryan C. HansonEVPSell15,272$87.11$1,330,343.92View SEC Filing  
6/3/2016Richard KuntzVPSell49,905$82.60$4,122,153.00View SEC Filing  
4/1/2016Richard KuntzVPSell4,000$75.22$300,880.00View SEC Filing  
3/18/2016Shirley A JacksonDirectorSell1,238$75.60$93,592.80View SEC Filing  
3/17/2016Omar IshrakCEOSell23,799$76.15$1,812,293.85View SEC Filing  
3/4/2016Bryan C HansonEVPSell5,000$75.00$375,000.00View SEC Filing  
2/5/2016Bryan C. HansonEVPSell5,000$76.14$380,700.00View SEC Filing  
1/8/2016Bryan C HansonEVPSell5,000$75.00$375,000.00View SEC Filing  
12/4/2015Richard KuntzVPSell13,715$78.06$1,070,592.90View SEC Filing  
9/15/2015Omar IshrakCEOSell20,000$69.43$1,388,600.00View SEC Filing  
7/14/2015Carol A SurfaceSVPSell13,722$75.83$1,040,539.26View SEC Filing  
4/6/2015Richard KuntzVPSell31,768$77.39$2,458,525.52View SEC Filing  
3/25/2015Gary Lee EllisCFOSell43,183$77.81$3,360,069.23View SEC Filing  
3/13/2015Omar IshrakCEOSell20,000$76.24$1,524,800.00View SEC Filing  
2/19/2015Christopher J OconnellEVPSell50,361$78.22$3,939,237.42View SEC Filing  
12/19/2014Richard KuntzVPSell12,855$74.54$958,211.70View SEC Filing  
12/2/2014Shirley A JacksonDirectorSell1,102$74.43$82,021.86View SEC Filing  
11/28/2014Christopher J OconnellEVPSell42,921$73.95$3,174,007.95View SEC Filing  
10/6/2014Christopher J OconnellEVPSell15,388$64.98$999,912.24View SEC Filing  
8/26/2014Christopher J OconnellEVPSell28,000$63.57$1,779,960.00View SEC Filing  
8/26/2014Shirley A JacksonDirectorSell2,769$63.66$176,274.54View SEC Filing  
4/17/2014Catherine SzymanVPSell29,420$58.79$1,729,601.80View SEC Filing  
4/9/2014Richard KuntzVPSell2,512$60.98$153,181.76View SEC Filing  
4/1/2014Gary Lee EllisCFOSell4,246$61.48$261,044.08View SEC Filing  
3/28/2014Christopher OconnellEVPSell1,982$60.39$119,692.98View SEC Filing  
3/20/2014Catherine SzymanVPSell14,979$59.57$892,299.03View SEC Filing  
3/14/2014Omar IshrakCEOSell10,000$59.12$591,200.00View SEC Filing  
3/10/2014Neil AyotteVPSell1,845$59.64$110,035.80View SEC Filing  
12/4/2013Neil AyotteVPSell1,729$57.14$98,795.06View SEC Filing  
9/13/2013Omar IshrakCEOSell10,000$53.58$535,800.00View SEC Filing  
8/26/2013Catherine SzymanVPSell56,998$52.60$2,998,094.80View SEC Filing  
8/22/2013H James DallasVPSell32,332$53.19$1,719,739.08View SEC Filing  
8/21/2013H James DallasVPSell36,256$52.82$1,915,041.92View SEC Filing  
8/21/2013Shirley JacksonDirectorSell8,033$52.84$424,463.72View SEC Filing  
7/11/2013Christopher J OconnellEVPSell30,429$52.92$1,610,302.68View SEC Filing  
7/11/2013Gary Lee EllisCFOSell32,602$53.62$1,748,119.24View SEC Filing  
7/11/2013H James DallasVPSell69,889$53.72$3,754,437.08View SEC Filing  
7/1/2013H James DallasVPSell20,579$52.10$1,072,165.90View SEC Filing  
6/26/2013D Cameron FindlayVPSell75,042$52.20$3,917,192.40View SEC Filing  
6/19/2013H James DallasVPSell94,117$52.74$4,963,730.58View SEC Filing  
5/22/2013Richard H AndersonDirectorBuy4,800$52.32$251,136.00View SEC Filing  
5/10/2013Jack W SchulerDirectorSell34,230$48.24$1,651,255.20View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Medtronic PLC (NYSE:MDT)
News IconMedtronic plc (MDT): The Technicals As Seen Today - NY Stock News (NYSE:MDT) - February 23 at 11:32 PM
News IconWhy to Keeping Eye on Medtronic plc (MDT), The Walt Disney Company (DIS)? - StockNewsJournal (NYSE:MDT) - February 23 at 11:32 PM
News IconDrilling Down Into the Charts for Medtronic plc (MDT) - The USA Commerce (NYSE:MDT) - February 23 at 11:32 PM logoNew Solitaire(TM) Stent Retriever Study Validates Outcomes and Real-World Application of Stroke Treatment Best Practices (NYSE:MDT) - February 23 at 6:32 PM
News IconCritical Chart Information For Medtronic plc (MDT) - NY Stock News (NYSE:MDT) - February 23 at 6:47 AM logoWedbush Maintains Neutral Rating and $85 PT on Medtronic (MDT) Following F3Q17 Results - (NYSE:MDT) - February 23 at 6:47 AM
News IconForward Earnings Estimate of Medtronic PLC(MDT) - Highland Mirror (NYSE:MDT) - February 23 at 6:47 AM
News IconJNBA Financial Advisors Has $3337000 Stake in Medtronic PLC (MDT) (NYSE:MDT) - February 22 at 6:37 PM logoEdited Transcript of MDT earnings conference call or presentation 21-Feb-17 1:00pm GMT (NYSE:MDT) - February 22 at 6:36 PM logoMedtronic 3Q Earnings Beat Street (NYSE:MDT) - February 22 at 6:36 PM
News IconThe Charts For Medtronic plc (MDT) Is Speaking Volumes Today - NY Stock News (NYSE:MDT) - February 22 at 8:19 AM
News IconAnalyst's Predictions on Medtronic plc (MDT), Abbott Laboratories (ABT) - StockNewsJournal (NYSE:MDT) - February 22 at 8:19 AM
News IconThe Technical Facts on Medtronic plc (MDT) - The USA Commerce (NYSE:MDT) - February 22 at 8:19 AM
News IconMedtronic Earnings Fall, Sales Rise -- Update (NYSE:MDT) - February 21 at 6:25 PM logoMedtronic plc Q3 Earnings Rise 3% (NYSE:MDT) - February 21 at 6:25 PM
News IconWhat you need to know about Medtronic plc’s (MDT) future? (NYSE:MDT) - February 21 at 6:25 PM logoMedtronic Plc (MDT) Q3 2017 Results - Earnings Call Transcript (NYSE:MDT) - February 21 at 6:25 PM logoMedtronic PLC Earnings Call scheduled for 8:00 am ET today (NYSE:MDT) - February 21 at 6:25 PM logoMedtronic (MDT) Beats on Q3 Earnings & Revenues Estimates (NYSE:MDT) - February 21 at 6:25 PM logo[$$] Medtronic Earnings Fall, Sales Rise (NYSE:MDT) - February 21 at 6:25 PM logoMedtronic's spine division sees strongest performance in seven years (NYSE:MDT) - February 21 at 6:25 PM logoMedtronic Posts 'Quickest Comeback' On Heart-Valve, Brain Therapies (NYSE:MDT) - February 21 at 6:25 PM
News IconMedtronic PLC (MDT) Set to Announce Quarterly Earnings on Tuesday (NYSE:MDT) - February 18 at 5:43 PM logo8:01 am Medtronic announces Japan regulatory approval for the world's smallest pacemaker, the Micra Transcatheter Pacing System (NYSE:MDT) - February 17 at 7:53 PM
News IconAnalysts Near-Term outlook: Eli Lilly and Company (LLY), Medtronic plc (MDT) - The USA Commerce (NYSE:MDT) - February 17 at 2:52 PM
News IconThe Case for and Against Medtronic plc (MDT) - StockNewsJournal (NYSE:MDT) - February 17 at 2:52 PM logoJefferies Reiterates Buy and $88 PT on Medtronic (MDT) Ahead of 3Q17 Report - (NYSE:MDT) - February 17 at 2:52 PM
News IconTraders Secrets on Medtronic plc (MDT), TechnipFMC plc (FTI) - StockNewsJournal (NYSE:MDT) - February 17 at 2:52 PM
News IconUBS Just Issued “Buy” Rating on Medtronic PLC (MDT) - Highland Mirror (NYSE:MDT) - February 17 at 2:52 PM logoMedtronic Announces Japanese Regulatory Approval for Micra(TM) Transcatheter Pacing System (TPS) (NYSE:MDT) - February 17 at 2:52 PM logoMedtronic Plc. (NYSE:MDT) Launches New Tools In Coronary Portfolio (NYSE:MDT) - February 16 at 6:05 PM logoMedtronic''s OsteoCool(TM) RF Ablation System Receives Expanded Indication for Palliative Treatment of Metastatic Bone Tumors (NYSE:MDT) - February 16 at 6:05 PM logoMedtronic (MDT) Gains FDA Approval for Expanded Indication of Freezor Xtra Cryoablation Catheter (NYSE:MDT) - February 16 at 6:05 PM logoMedtronic Introduces Signia(TM) Stapling System, Innovative Surgical Stapler for Minimally Invasive Surgery (NYSE:MDT) - February 16 at 6:05 PM logo12:01 pm Medtronic announces FDA approval for its Freezor Xtra Cryoablation Catheter for treating patients with atrioventricular nodal re-entrant tachycardia (NYSE:MDT) - February 16 at 6:05 PM logoFDA Approves Expanded Indication for Medtronic Freezor® Xtra Cryoablation Catheter (NYSE:MDT) - February 16 at 6:05 PM
News IconMedtronic PLC (MDT) Launches New Tools In Coronary Portfolio (NYSE:MDT) - February 15 at 10:27 AM logoThese drug and medical device companies made the most payments to L.A. hospitals (NYSE:MDT) - February 14 at 5:41 AM logoMedtronic : Expands Coronary Portfolio to Include New DxTerity(TM) Diagnostic Catheters and Suite of Tools for the Transradial Approach (NYSE:MDT) - February 13 at 7:37 PM
News IconMedtronic Goes Radial (NYSE:MDT) - February 13 at 7:37 PM logoMedtronic : Announces New, Outcome-Based Learning Program (NYSE:MDT) - February 13 at 10:23 AM logoMedtronic Expands Coronary Portfolio to Include New DxTerity(TM) Diagnostic Catheters and Suite of Tools for the Transradial Approach (NYSE:MDT) - February 13 at 10:23 AM logoMedtronic EVP & President Michael J. Coyle to Speak at RBC Capital Markets Global Healthcare Conference (NYSE:MDT) - February 13 at 10:23 AM
News IconThe BP PLC (BP) Sees Significant Increase in Short Interest (NYSE:MDT) - February 11 at 6:37 PM
News IconChecking Out the Technicals for Medtronic plc (MDT) - The USA Commerce (NYSE:MDT) - February 11 at 12:22 AM
News IconAnalyst's Predictions on Medtronic plc (MDT), CBS Corporation (CBS) - StockNewsJournal (NYSE:MDT) - February 11 at 12:22 AM
News IconEquity Perception: Analyst's Indicator Review for Medtronic plc (MDT), Franklin Resources, Inc. (BEN) - The USA Commerce (NYSE:MDT) - February 11 at 12:22 AM logoMedtronic to Announce Financial Results for Its Third Quarter of Fiscal Year 2017 (NYSE:MDT) - February 10 at 7:19 PM logoMedtronic (MDT) Says First DCB Study Results in Japan Demonstrate Consistent Clinical Outcomes (NYSE:MDT) - February 10 at 5:32 AM
News IconStock for Your Case: Medtronic plc (NYSE:MDT) (NYSE:MDT) - February 10 at 12:31 AM


What is Medtronic PLC's stock symbol?

Medtronic PLC trades on the New York Stock Exchange (NYSE) under the ticker symbol "MDT."

How often does Medtronic PLC pay dividends? What is the dividend yield for Medtronic PLC?

Medtronic PLC announced a quarterly dividend on Friday, December 9th. Investors of record on Friday, December 23rd will be paid a dividend of $0.43 per share on Friday, January 13th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 2.13%. The ex-dividend date of this dividend is Wednesday, December 21st.

Where is Medtronic PLC's stock going? Where will Medtronic PLC's stock price be in 2017?

25 equities research analysts have issued 1 year price targets for Medtronic PLC's shares. Their predictions range from $77.00 to $102.00. On average, they expect Medtronic PLC's stock price to reach $87.71 in the next twelve months.

When will Medtronic PLC announce their earnings?

Medtronic PLC is scheduled to release their next quarterly earnings announcement on Tuesday, February, 21st 2017.

What are analysts saying about Medtronic PLC stock?

Here are some recent quotes from research analysts about Medtronic PLC stock:

  • According to Zacks Investment Research, "Medtronic posted better-than-expected fiscal third-quarter results with both earnings and revenues ahead of the Zacks Consensus Estimate. All major business groups contributed to solid top-line growth at CER indicating sustainability across groups and regions. However, escalating costs and expenses weighed on margins. Also, unfavorable foreign exchange continues to remain a drag. This has been reflected in the company’s share price trend too. In the past 6 months, Medtronic consistently traded below the Zacks categorized Medical Product industry and a dull fiscal guidance fails to indicate any chances of respite soon. On a positive note, we are encouraged by the solid growth trend in the U.S. as well as the healthy global acceptance of its therapies. Apart from product innovation, the company is currently focusing on geographical diversification of its businesses." (2/23/2017)

  • Wedbush analysts commented, "Medtronic's broad product portfolio allows the company to navigate through temporary disruptions it might encounter in any given business unit, and today's FY3Q17 earnings results showcased management's ability to leverage its size and recover more quickly than we had expected from its disappointing FY2Q17 performance reported in November. With MDT's share price having mostly recovered from the post FY2Q17 selloff, we believe current valuation levels adequately reflect MDT's risk/reward profile and prefer to wait on the sidelines for a better entry point. ' FY3Q17 revenue of $7,283 million (+6% yr/yr, ex-FX) beat consensus revenue estimate of $7,220 million. Revenue from all four segments exceeded consensus, with the biggest contribution from Minimally Invasive Therapies Group (MTIG) and Diabetes' Our $85 PT is based on applying a 16x P/E multiple on our MDT forward EPS estimate, 12 months hence." (2/22/2017)
  • Needham & Company LLC analysts commented, "F3Q17 revenue and EPS beat consensus and MDT maintained its FY17 guidance. Organic revenue growth increased to 4.1% CC vs. 2.2% CC in F1Q17 with new products adding ~390 bps, emerging markets adding ~150 bps and services & solutions adding ~20 bps (yielding reported revenue growth of 5.6% CC). Operating margin was just below consensus and up 40 bps Y/Y (or 130 bps Y/ Y CC). Importantly, management reiterated its longer-term target of mid-single digit revenue growth and double-digit EPS growth. MDT noted it expects to offset the impact of competitors' new product launches (e.g. MRI devices) with its own new product launches. MDT shares remain at a discount to peers and we reiterate our Buy rating." (2/21/2017)
  • Evercore ISI analysts commented, "MDT started 2017 with a solid execution, highlighted by all around revenue beat and operating margins that were generally in line with ST (came in above us). The importance of this Q cannot be underestimated in our mind, as sentiment had turned negative (post a disappointing 1H) and the stock multiple (3-6x discount to peer group) was see-sawing precariously at ~15-16x P/E. While the bar had been lowered, MDT needed to deliver to flawless Q to instill investor confidence and start the path towards multiple correction (vs. group). The company began its first step, highlighted by a solid revenue beat, driven by high single digit growth in CR&HF. This is a key segment, and the ~8% growth should provide comfort against the bear thesis of competitive share losses / replacement cycle headwinds. We were also encouraged to see ~30% growth in TAVR, and a full rollout of the 34mm valve (launched only in 50% of centers) plus Intermediate Risk approval in early 2018 bodes well. Other key drivers in 2018 include the full commercial launch of 670G in Diabetes, Resolute Onyx launch, continued growth in AF, Link, DCBs, and the continued turnaround in Spine provides incremental confidence in MDT being able to sustain ~4% organic topline in the medium term. The second leg of value creation will rest on margin expansion, with the ST still skeptical of the company's ability to show margin expansion on a reported basis (including the impact of Fx hedges). We believe that the margin expansion thesis will play out in 2018, and will play a huge role in MDT's ability to close its P/E gap vs. peer group average. We expect this combination of a potential multiple reflation trade along with upside from capital deployment (incremental ~$3 Bn could potentially be accessible in near term post IRS settlement) to drive value for investors over the next 12 months." (2/21/2017)
  • Jefferies Group LLC analysts commented, "Heading into results next week, we are updating our model for FX and revisiting some of the recent themes at MDT. Among the issues to watch: FX gains will again confound the outlook, with FY18 consensus numbers likely too high; the pace of underling margin gains against the targets laid out last year; and how increasing competition in CRM, Neuro, TAVR, etc can be offset by Spine, Diabetes, Robotics, EM, etc to keep growth in the mid-single digits." (2/17/2017)

Who owns Medtronic PLC stock?

Medtronic PLC's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include State Street Corp (4.66%), FMR LLC (4.29%), Franklin Resources Inc. (2.71%), Artisan Partners Limited Partnership (1.74%), Barrow Hanley Mewhinney & Strauss LLC (1.50%) and Dimensional Fund Advisors LP (0.58%). Company insiders that own Medtronic PLC stock include Bryan C Hanson, Carol A Surface, Gary Lee Ellis, Geoffrey Martha, James T Lenehan, Kendall J Powell, Omar Ishrak, Richard Kuntz, Robert C Pozen and Shirley A Jackson.

Who sold Medtronic PLC stock? Who is selling Medtronic PLC stock?

Medtronic PLC's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Artisan Partners Limited Partnership, I.G. Investment Management LTD., Federated Investors Inc. PA, Institutional Capital LLC, Marshall Wace LLP, Bessemer Group Inc. and Comgest Global Investors S.A.S.. Company insiders that have sold Medtronic PLC stock in the last year include Bryan C Hanson, Carol A Surface, Gary Lee Ellis, Geoffrey Martha, Kendall J Powell, Omar Ishrak, Richard Kuntz and Shirley A Jackson.

Who bought Medtronic PLC stock? Who is buying Medtronic PLC stock?

Medtronic PLC's stock was acquired by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Russell Investments Group Ltd., DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main, Janus Capital Management LLC, Barrow Hanley Mewhinney & Strauss LLC, State Street Corp, Equity Investment Corp Acquisition Inc and Thrivent Financial for Lutherans. Company insiders that have bought Medtronic PLC stock in the last two years include James T Lenehan and Robert C Pozen.

How do I buy Medtronic PLC stock?

Shares of Medtronic PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Medtronic PLC stock cost?

One share of Medtronic PLC stock can currently be purchased for approximately $80.74.

Medtronic PLC (NYSE:MDT) Chart for Friday, February, 24, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for Medtronic PLC (NYSE:MDT)

Earnings History Chart

Earnings by Quarter for Medtronic PLC (NYSE:MDT)

Dividend History Chart

Dividend Payments by Quarter for Medtronic PLC (NYSE:MDT)

Last Updated on 2/24/2017 by Staff